One of my primary commitments is to keep you up-to-date on the latest osteoporosis news, including the most recent osteoporosis research and drugs. Today you’ll read about a newly discovered side effect of a blockbuster drug and the mysterious delay for approval application of what could become the next best-selling osteoporosis drug.
So let’s get started…
In addition to the already known, dangerous side effects of the very popular blood thinner Plavix, a new study has surprised researchers with its results.The study, conducted by Danish researchers, showed that Plavix increased osteoporosis risk by 50 percent in those taking the drug.
Researchers included in the study other blood thinners that have the same active ingredient: clopidogrel, so it seems that this substance is the culprit.
Increased Osteoporosis Risk is One of Many Side Effects of Plavix
Compared to the lengthy list of known side effects of Plavix, the increased risk of osteoporosis just discovered can be considered one of the least dangerous. Other side effects include hemorrhage, such as bleeding under the skin, nosebleeds, and brain hemorrhage.
And ironically, while the drug is prescribed to prevent recurring heart attacks and strokes, Plavix affects the cardiovascular system. Side effects such as heart failure, chest pain, edema, and hypertension in addition to syncope, palpitations, and atrial fibrillation are also included in the long list of side effects.
And it gets worse. As its manufacturer warns, “Plavix can cause bleeding which can be serious and can sometimes lead to death.”1
The nervous system is not immune to the side effects of Plavix either – dizziness and headaches can occur as a result of taking Plavix. And last but not least, insomnia and back pain have also been reported.
“Danish researchers surprisingly conclude that the blood-thinning drug may increase the risk of patients developing osteoporosis – also known as brittle bone disease – and thus risk breaking e.g. their spine, hips or wrists.
‘It appears that the risk of developing osteoporosis increases by around 50 percent, primarily for people who have been taking the drug for a year or longer,’ says Niklas Rye Jørgensen, chief physician at Glostrup Hospital. ‘This is interesting because Plavix has been a “blockbuster drug” for some years now, where it’s been number one and two on the list of best-selling drugs in the world, so many people are affected. And the harmful effect may be quite considerable.’ …
Together with Danish and international colleagues, Jørgensen has examined 77,000 Danish patients, who in the period 1998-2008 were treated with Plavix or other drugs which, like Plavix, contain the active substance clopidogrel. … After having adjusted for other factors that may affect the risk of osteoporosis, the researchers were left with something that looks like a clear conclusion: patients on clopidogrel have a far greater incidence of broken hips and wrists as well as spinal collapse than those who have never taken clopidogrel.” 2
Merck has just announced that the application for regulatory approval of its newest osteoporosis drug will be delayed. The reason for this remains a mystery, but based on the secrecy about the negative side effects of the latest Phase III trial, it is likely that there are some nefarious side effects to this drug that, at least for now, Merck has chosen not to reveal.
Odanacatib is not a bisphosphonate; it works via a different mechanism, but the effect is essentially the same. Odanacatib blocks an enzyme called cathespin K that’s responsible for the healthy breakdown and resorption of bone. If you got the Osteoporosis Reversal Program, you have a good understanding of bone remodeling, which is the process by which old bone is broken down and replaced with new bone.
“Merck said on Friday that it would delay seeking approval for an experimental osteoporosis drug, an announcement that helped send the company’s shares down 3 percent on the same day it announced its fourth-quarter earnings for 2012.
Company executives told analysts in a conference call Friday morning that Merck was delaying its application for the drug, odanacatib, because it is seeking additional data from a clinical trial. But they said they remained confident in the drug’s ultimate chances for approval and would submit their application in 2014.” 3
There’s No Such Thing as a 100% Safe Osteoporosis Drug
It’s more than likely that Big Pharma will pull off yet another profitable deception, obtaining approval and raking in huge profits before dangerous new side effects are discovered in the longer term.
The bottom line is that there never has been and never will be an osteoporosis drug that’s safe. While the methods and chemicals differ, at the most basic level all of these drugs are designed to counteract and thwart a natural process: bone remodeling. And the effects of these drugs are far-reaching and often devastating.
Fortunately, There is a 100% Safe Alternative to Treat Osteoporosis
The Osteoporosis Reversal Program is 100% safe and 100% natural, scientifically-proven and doctor-approved. And it has changed lives for the better in great part by giving community members full control of their bone health with absolutely no risk of dangerous side effects.
Essentially, the Osteoporosis Reversal Program is a nutritional, lifestyle, and exercise plan designed to improve bone density naturally, and to help you build strong and healthy bones. And there are no drugs involved!
Till next time,
2 Hoffman, Thomas. “Bestseller drug may cause osteoporosis.” Science Nordic. January 31, 2013. Web. http://sciencenordic.com/bestseller-drug-may-cause-osteoporosis
3 Thomas, Katie. “Merck Delays Osteoporosis Drug.” The New York Times. February 1, 2013. Web. http://www.nytimes.com/2013/02/02/business/merck-delays-osteoporosis-drug.html?_r=2&